Macromoltek
Computational antibody design
Monica Berrondo, Susana Kaufmann · 2 co-founders
Profile coverage4 of 8 · missing Funding, Signals, Customers, Stack / tools · last run 8/11/2026
About
Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.